It's already been established that type 2 diabetes increases the risk of pancreatic cancer. And now, research indicates there is also a link between type 1 diabetes and this type of cancer.

The risk is relatively small -- but still, those with type 1 diabetes have a likelihood of developing pancreatic cancer that is twice as high as in non-diabetics. This is similar to the risk those with type 2 diabetes face.

There are many theories about the link between diabetes and pancreatic cancer, and this research -- published in the British Journal of Cancer -- helps narrow the scope of the theories.

For example, one researcher says the study rules out "a cancer-inducing role of the insulin-producing beta-cells in the pancreas, because in type 1 diabetes these cells have largely or entirely been destroyed."

Experts say people with diabetes should focus their attention on the most common complications of diabetes such as heart disease, eye disease, and kidney disease and not on the very small risk of cancer. In the whole scheme of things, pancreatic cancer is a rare disease -- and even twice the risk is not very significant.

The CyberKnife -- a powerful new weapon in the war on cancer -- involves no cutting, like the name implies. This robotic system instead uses hundreds of focused radiation beams to destroy a tumor. A robotic arm moves around the patient and an image-guided system tracks the targeted tumor. CyberKnife delivers small blasts of radiation from up to 200 angles and keeps the tumor in its sights at all times. CyberKnife treatments are completed in one to five days which is just one of the benefits of this therapy compared to traditional radiation therapy.

With traditional radiation, patients often endure treatment for five to eight weeks. And healthy tissue can be destroyed every time the patient shifts or breathes. The CyberKnife attacks the cancerous tumor only -- even while the patient breathes. CyberKnife therapy, available in only 50 hospitals in the United States, requires no mold to position patients, can treat anywhere in the body, and can help patients who no longer respond to traditional treatments.

CyberKnife is covered by insurance and approved by Medicare.

Husband and wife team -- Dr. Tyler Curiel and Dr. Ruth Berggren -- prepare to relocate to San Antonio, Texas and will leave behind the city torn apart by Hurricane Katrina -- the same city where they worked tirelessly in 100-plus degree heat to rescue frozen cells and tissue from destruction during a storm that destroyed nearly everything in its path. They worked for one week caring for trapped patients at the inner city Charity Hospital, using diminishing generator power and the very basic of supplies. And they worked by flashlight to preserve their temperature-sensitive cells -- the cells that made up most of their life's work. They were successful in their mission -- and happily saved the cells of one of Curiel's medical students who once worked in his lab but died in 2004 of a rare cancer.

In September, the duo will leave New Orleans and will begin work at a nationally recognized cancer center -- the San Antonio Cancer Institue. Curiel will share his expertise in gynecological cancers -- specifically ovarian cancer -- and Berggren will join the health science center as an infectious disease specialist.